University of California San Francisco

Transplant Immunology

Organ transplantation is often the only clinical option available for treating certain types of cardiovascular disease. While frequently successfully performed, organ transplantation is often accompanied by immune system complications that result in rejection. The TSI Lab is highly motivated toward designing methods to help prevent such rejection, ranging from investigating the immunogenicity of matrix components of bioengineered tissue for transplantation (Conradi et al. 2015), to use of techniques that allow visualization of immune responses after transplantation (Conradi et al. 2011), to identifying novel immunosuppressants for prevention of acute cardiac graft rejection (Deuse et al. 2012). The TSI Lab continues to develop new concepts to identify and prevent immune rejection post-transplantion.

Related Publications

Conradi L, Pahrmann C, Schmidt S, Deuse T, Hansen A, Eder A, Reichenspurner H, Robbins RC, Eschenhagen T, Schrepfer S 
Bioluminescence imaging for assessment of immune responses following implantation of engineered heart tissue (EHT). 
Journal of visualized experiments : JoVE, 2011;[epublish](52).

 

Conradi L, Schmidt S, Neofytou E, Deuse T, Peters L, Eder A, Hua X, Hansen A, Robbins RC, Beygui RE, Reichenspurner H, Eschenhagen T, Schrepfer S 
Immunobiology of fibrin-based engineered heart tissue. 
Stem cells translational medicine, Jun-2015;4(6):625-31.  Epub 2015 May 6.

Deuse T, Hua X, Taylor V, Stubbendorff M, Baluom M, Chen Y, Park G, Velden J, Streichert T, Reichenspurner H, Robbins RC, Schrepfer S 
Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 
Transplantation, Oct-15-2012;94(7):695-702.